Trevena Announces Receipt of Milestone Payment From Partner in China Jiangsu Nhwa Pharmaceutical May 31, 2023 7:00am EDT
Trevena Regains Compliance with Nasdaq Listing and Reaffirms Expected Near-Term Milestones May 30, 2023 7:00am EDT
Trevena Announces Initial Topline OLINVYK Data from ~200 Patient Real-World Clinical Outcomes Study Mar 30, 2023 7:02am EDT
Trevena to Release Fourth Quarter and Full Year 2022 Financial Results on March 30, 2023 Mar 27, 2023 7:00am EDT
Trevena Initiates Targeted Proof-of-Concept Study to Evaluate TRV045 as a Potential Treatment for Epilepsy and Other CNS Disorders Mar 07, 2023 7:00am EST
